Printer Friendly

STUDY ON OVULATION INDUCTION WITH CLOMIPHENE CITRATE, METFORMIN, HUMAN CHORIONIC GONADOTROPIN AND HUMAN MENOPAUSAL GONADOTROPIN IN FEMALE INFERTILITY.

BACKGROUND

Infertility is defined as one year of unprotected intercourse without pregnancy. [1] This condition is further classified as primary infertility and secondary infertility. Normal ovulation requires co-ordination of neuro-endocrinal system at all levels i.e. central hypothalamic-pituitary axis, the feedback signal & local response within the ovary. An ovulatory disorders are commonly due to polycystic ovarian syndrome, hypogonadotropic hypogonadism hyperprolactinaemia & hypothyroidism.

Induction of ovulation is indicated in-

1. Anovulatory infertile women (commonest cause)

2. Timing of ovulation in irregularly ovulating women

3. Oocyte maturation for in-vitro fertilization

4. As a test of pituitary or ovarian function. Clomiphene citrate, human chorionic gonadotropin (HCG), human menopausal gonadotropin (HMG), metformin are the commonly used drugs for ovulation induction. They are used alone or in combination with ultrasound monitoring. Ovulation is documented by monitoring the development of a dominant follicle by ultrasound until ovulation takes place. Ovulation is characterized by a decrease in the size of a monitored ovarian follicle and by the appearance of fluid in the cul-de sac. [2,3]

Commercially available kits for documenting the LH surge are generally accurate, quick convenient and relatively inexpensive. [4] The least expensive method of confirming ovulation is for the patient to her temperature each morning on a basal body temperature chart. The oral or rectal temperature should be determined before the patient arises, eats or drinks.

METHODS

Our study was a Interventional study and was done to induce ovulation among 100 infertile women (Sample size taken as per convenience) having oligo-ovulation or anovulation. It was conducted at the department of Obstetrics & Gynaecology, Calcutta National Medical College & Hospital, Kolkata from February 2017 to August 2018. The study population was selected from the couples attending the outpatient department. Cases were also selected from those admitted in the in-patient department for evaluation of their infertility status. Infertility status of all couples was evaluated by history from both partners; clinical examination and different routine and specific tests for infertility, so that the cause of their infertility could be detected. Only those couples were undertaken for this study in whom oligo-ovulation or anovulation was suspected. Ovulation was detected by ultrasonography.

Inclusion Criteria

1. Woman who failed to conceive after staying with her husband at least for 1 year without any contraception

2. Both partner in fertile age group.

Exclusion Criteria

1. Abnormal semen analysis of the husband

2. Uterus is not morphologically normal and any of the fallopian tubes is not patent by hystero-salpingography or laparoscopic chromopertubation.

3. Patients with functional ovarian cyst, neoplastic ovarian cyst or ovarian failure.

4. Patients with liver disorders, Visual disturbances (blurred or double vision, scotoma and light sensitivity)

5. Patients with hyperprolactinaemia, hypothyroidism, diabetes mellitus.

6. Patients treated with ovulation inducing drugs in last 3 months.

Aims and Objectives

To evaluate the following effects of ovulation inducing agents in a case of primary or secondary infertility-

1. Ovulation rate by ultrasound monitoring.

2. Viable pregnancy rate ([greater than or equal to] 28 weeks).

3. Abortion rate.

4. Side effects like multiple pregnancies & ovarian hyper stimulation syndrome (OHSS)

RESULTS

Out of the 100 couples studied, primary infertility was found in 80% and secondary infertility in 20%. Incidence of primary infertility was 4 times than that of secondary infertility.

Most of the cases (80%) in our study presented at a younger age group (i.e. 20-30 years). Maximum number of cases were between 26-30 years of age (55 Cases) and next between 20-25 years of age (25 Cases).

In our study the duration of infertility ranged from 2 years to 20 years and it was observed that 70% of the cases presented within 7 years of infertility.

In 65% cases, therapy for ovulation induction used was clomiphene alone. In 35% cases, metformin was given alone. 48% patients were given clomiphene with metformin in whom ovulation did not occur with clomiphene alone or metformin alone. Clomiphene with HCG was given in 18% patients in whom ovulation fails to occur with clomiphene with metformin. Rest 6% were given clomiphene with HCG & HMG in whom ovulation did not occur with clomiphene with HCG.

Table I shows that 65 patients were started with 50 mg clomiphene; in whom ovulation did not occur (48 Patients), they were given 100 mg clomiphene. 150 mg clomiphene given in those (38 Patients) who did not ovulate with 100 mg dose.

Total ovulation rate with clomiphene were 53.84% and pregnancy rate were 35.38%.

With clomiphene, viable pregnancy rate was 29.23% (19 cases), spontaneous abortion rate were 06.15% (4 cases), rate of multiple pregnancy were 04.61% (3 cases) & rate of OHSS were 06.15% (4 cases).

Only metformin was given to 35 patients for one month; in whom ovulation did not occur metformin was continued for one more month and it was continued for three months in those who did not ovulate after two months of the drug. Total ovulation rate was 48.57% and pregnancy rate was 42.85% (Table II)

With metformin alone the viable pregnancy rate was 34.28% (12 cases); rate of spontaneous abortion was 08.57% (3 cases); no cases of multiple pregnancy and OHSS found.

Out of 48 patients treated with clomiphene and metformin, 30 patients ovulated & 21 patients conceived. Maximum number of ovulations occurred in 3rd cycle. (Table III). The viable pregnancy rate was 37.50% (18 cases); spontaneous abortion rate was 06.25% (3 cases); rate of multiple pregnancy and OHSS were 02.08% (1 case) and 04.16% (2 cases) respectively.

Ovulation & conception rate was highest in 2nd cycle where 150 mg clomiphene was used from 2nd day of menstruation for 5 days & USG done for ovulation profile on 10th day onwards till the follicular size was of 18 mm & then Inj HCG (5, 000 IU) given IM.

With clomiphene & HCG total rate of ovulation were 66.66% and total rate of conception were 50% (Table IV). With clomiphene & HCG rate of viable pregnancy were 38.88% (7 cases), rate of spontaneous abortion were 11.11% (2 cases), rate of OHSS were 22.22% (4 cases). No case of multiple pregnancies found.

Clomiphene, HCG and HMG were prescribed only in 6 cases and for three cycles as it was cost effective to monitor the cases. Out of these patients 3 ovulated & 2 conceived. (Table V). Rate of viable pregnancy were 33.33% (2 cases) & rate of OHSS were 33.33% (2 cases). No case of multiple pregnancy and spontaneous abortion found.

Efficacy and complications of different ovulation inducing agents is summarized in table VI.

DISCUSSION

In this study group of 100 cases of infertility 80% were primary infertility and 20% were of secondary infertility and maximum number of cases belong to the age group 26-30 years (55%). We are well acquainted with the social customs of our country which favour early marriage & quick childbearing. These accounts for the high number of cases were in young age group.

The maximum number (70%) of cases presented within 7 years of marriage. Mean duration of infertility was 5 years whereas in cases of secondary infertility the duration was more. Study by WHO (Dec. 1980 to Sept. 1983 in the university clinic of Kandang Kerban Hospital) reported 3.2 years was the duration of infertility which is less than our study group. This can be explained with reference to the social custom & beliefs of the society.

So, in our study it was found that ovulatory response is better with combination of clomiphene & metformin than clomiphene alone or metformin alone which is similar to the result of the study done by Zain MM et al in 20095. We found that the ovulatory response was least with metformin alone.

Regarding pregnancy rate, metformin alone and combination of clomiphene & metformin are almost similar in efficacy but both are superior to clomiphene alone.

In our study 18 patients were treated with clomiphene with HCG (In whom ovulation failed to occur even with clomiphene with metformin).) Total rate of ovulation with clomiphene & HCG were 66.66% and total rate of conception were 50%. Ovulation & conception rate was highest in 2nd cycle where 150 mg clomiphene was used.

In our study 6 patients were treated with clomiphene with HMG & HCG and ovulation rate was approximately 50% & conception rate 33.33 %. OHSS is an important iatrogenic side effect of ovulation inducing drugs specially clomiphene, HCG & HMG.

The reported incidence of OHSS is highly variable according to different studies because various classifications are used. Furthermore, these studies relate to very different clinical situations such ovulation induction using gonadotrophins or clomiphene citrate, or ovarian stimulation during IVF, which are not comparable in terms of therapeutic goals and strategies. ESHRE report on ART in Europe in 2004 found an incidence of OHSS of 1.2% of all stimulated cycles, using register data from 25/29 countries. UK contributed 635 cases from 32, 632 cycles (1.94%). [6] In our study the total rate of OHSS is 12% (Total 12 cases among 100 patients). 4 cases found in clomiphene only treated patient, 2 cases found in patients who received clomiphene with metformin, 2 cases found in patients treated with clomiphene with HMG with HCG. Maximum incidence found in patients receiving clomiphene with HCG (4 out of 18).

The administration of drugs that induce ovulation to treat infertile couples has become more frequent in the last decade. Such drugs enhance the probability of multiple pregnancy and have been considered responsible for the increase in multiple births observed in recent years in some countries. In our study the incidence of multiple pregnancies was 4% (4 out of 100 cases, among which 3 were twin and one triplet). 3 cases found with the use of clomiphene citrate alone and one case found with the use of combination of clomiphene & metformin. This incidence was lower than other available studies [7]

The incidence of pregnancy wastage in my study was 12% (Total 12 abortions in 100 patients) which was much lower than other reported incidences. [8-11] This may be due to better evaluation of infertility cases.

CONCLUSIONS

Total 70 patients conceived out of total 100 patients studied and out of which 97 patients ovulated. Pregnancy rates were maximum with clomiphene with HCG (50%).

Among 70 patients conceived, 12 aborted in early pregnancies during study time. 58 patients gave birth to term babies. So, out of 100 patients studied, the viable pregnancy rates were 58%.

Among the complications of ovulation inducing drugs in my study, maximum evidence were both OHSS and pregnancy wastage; rate of each was 12%. The other is multiple pregnancies which occurred in 4 patients out of 100 patients (4%). The commonest type of multiple pregnancy was twin pregnancy (3 out of 4). Only one case of triplet pregnancy was found. Out of 12 cases of OHSS, 11 were mild cases and one was severe for which she was kept hospitalised for careful observation and treated with conservative management.

So, if there is correct evaluation of cases, by conveying psychological assurance, taking the couple into confidence and providing them a correct medical therapy, we can help them to become mothers and have happy families.

DOI: 10.14260/jemds/2019/400

'Financial or Other Competing Interest': None.

Submission 06-04-2019, Peer Review 25-05-2019, Acceptance 01-06-2019, Published 10-06-2019.

REFERENCES

[1] Berek JS. Berek & Novak's Gynaecology. 15th edn. Philadelphia, PA, 19103 USA: Lippincott Williams & Wilkins 2012.

[2] Kerin JF, Edmonds DK, Warnes GM, et al. Morphological & functional relations of Graafian follicle growth to ovulation in women using ultrasonic, laparoscopic and biochemical measurements. Br J Obstet Gynaecol 1981;88(2):81-90.

[3] O'Herlihy C, De Crespigny LC, Lopata A, et al. Preovulatory follicular size: a comparison of ultrasound and laparoscopic measurements. Fertil Steril 1980;34(1):24-6.

[4] Elkind-Hirsch K, Goldzieher JW, Gibbons WE, et al. Evaluation of the OvuSTICK urinary luteinizing hormone kit in normal and stimulated menstrual cycles. Obstet Gynecol 1986;67(3):450-3.

[5] Zain MM, Jamaluddin R, Ibrahim A, et al. Comparison of clomiphene citrate, metformin or the combination of both for first-line ovulation induction, achievement of pregnancy and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2009;91(2):514-21.

[6] Andersen AN, Goossens V, Ferraretti AP, et al. Assisted reproductive technology in Europe, 2004: results generated from European Registers by ESHRE. Hum Reprod 2008;23(4):756-71.

[7] Corchia C, Mastroiacovo P, Lanni R, et al. What proportion of multiple births are due to ovulation induction? A register-based study in Italy. Am J Public Health 1996;86(6):851-4.

[8] Gray RH, Wu LY. Subfertility and risk of spontaneous abortion. Am J Publ Health 2000;90(9):1452-4.

[9] Schindler AE. Moglichkeiten der Diagnostik und Therapie mit Clomifen. Frauenarzt 1990;31:253-70.

[10] Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the Polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87(2):524-9.

[11] Rai R, Backos M, Rushworth F, et al. Polycystic ovaries and recurrent miscarriage--a reappraisal. Hum Reprod 2000;15(3):612-5.

Corresponding Author:

Dr. Selim Akhtar, Neel Diganta Enclave, Flat No. 1-3, 3rd Floor, Block- B, Sethpukur P. O. + P. S., Barasat-700124, North 24 Parganas, West Bengal, India.

E-mail: s.akhtar19841984@gmail.com

Anuradha De Pati (1), Selim Akhtar (2), Nibedita Chattopadhyay (3), Susanta Banerjee (4)

(1) Associate Professor, Department of Pathology, School of Tropical Medicine, Kolkata, West Bengal, India.

(2) Residential Medical Officer Cum Clinical Tutor, Department of Obstetrics and Gynaecology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India.

(3) Professor, Department of Obstetrics and Gynaecology, Cooch Behar Government Medical College and Hospital, Cooch Behar, West Bengal, India.

(4) Professor and HOD, Department of Radiodiagnosis, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India.

Caption: Selected Patients were Studied as Per Protocol
Table I. Summary of Efficacy of Clomiphene Citrate

Dose of        No. of     No. of pts.    % of Total
Clomiphene   Pts. Given    Ovulated       Ovulated
(mg)                                      Patients

50               65           17        26.15 (17/65)
100          48 [65-17)       10        20.83 (10/48)
150          38 (48-10)       08        21.05 (08/38)
Total            65           35        53.84 (35/65)

Dose of        No. of      No. of      % of Total
Clomiphene   Pts. Given    Patient       Patient
(mg)                      Conceived     Conceived

50               65          12       18.48 (12/65)
100          48 [65-17)      06       12.50 (06/48)
150          38 (48-10)      05       13.15 (05/38)
Total            65          23       35.38 (23/65)

Table II. Summary of Efficacy of Metformin

No. of       No. of       No. of      % of Total
Months       Patient      Patient      Ovulation
Given         Given      Ovulation      Patient
Metformin

1               35          08       22.85 (08/35)
2           27 (35-08)      05       18.51 (05/27)
3           22 (27-05)      04       18.18 (04/22)
Total           35          17       48.57 (17/35)

No. of       No. of       No. of         % of
Months       Patient      Patient       Total
Given         Given      Conceived      Patient
Metformin                              Conceived

1               35          06       17.14 (06/35)
2           27 (35-08)      05       18.51 (05/27)
3           22 (27-05)      04       18.18 (04/22)
Total           35          15       42.85 (15/35)

Table III. Summary of Efficacy of Clomiphene with Metformin.

Cycles of     No. of      No. of      % of Total
Clomiphene    Patients    Patients     Ovulated
and            Given      Ovulated     Patients
Metformin

1st              48          08      16.66 (08/48)
2nd          40 (48-08)      08      20.00 (08/40)
3rd          32 (40-08)      14      43.75 (14/32)
Total            48          30      62.50 (30/48)

Cycles of     No. of       No. of       % Total
Clomiphene    Patients    Patients      Patients
and            Given      Conceived     Conceived
Metformin

1st              48          05       10.41 (05/48)
2nd          40 (48-08)      06       15.00 (06/40)
3rd          32 (40-08)      10       31.25 (10/32)
Total            48          21       43.75 (21/48)

Table IV. Summary of Efficacy of Clomiphene with HCG

Cycles of     No. of     No. of      % of Total
cc + HCG    Pts. Given    Pts.        Ovulated
                         Ovulated

1st             18          05      27.77 (05/18)
2nd         13 (18-05)      05      38.46 (05/13)
3rd         08 (13-05)      02      25.00 (02/08)
Total           18          12      66.66 (12/18)

Cycles of     No. of      No. of      % of Total
cc + HCG    Pts. Given     Pts.        Patients
                         Conceived     Conceived

1st             18          03       16.66 (03/18)
2nd         13 (18-05)      04       30.76 (04/13)
3rd         08 (13-05)      02       25.00 (02/18)
Total           18          09       50.00 (09/18)

Table V. Summary of Efficacy of Clomiphene, HMG & HCG.

Cycles of       No. of      No. of      % of Total
Clomiphene     Patients    Patients      Ovulation
+ HCG + HMG     Given      Ovulation     Patients

1st               06          00            00
2nd           06 (06-00)      01       16.66 (01/06)
3rd           05 (06-01)      02       40.00 (02/05)
Total             06          03       50.00 (03/06)

Cycles of       No. of      No. of      % of Total
Clomiphene     Patients    Patients      Patients
+ HCG + HMG     Given      Conceived     Conceived

1st               06          00            00
2nd           06 (06-00)      00            00
3rd           05 (06-01)      02        40 (02/05)
Total             06          02       33.33 (02/06)

Table VI. Summary of Efficacy & Complications of Different
Ovulation Inducing Agents.

BMI= Body mass index, CC= Clomiphene citrate, HCG= Human chorionic
gonadotropin, HMG= Human menopausal gonadotropin, VP= Viable
Pregnancy, OHSS= Ovarian Hyper stimulation Syndrome, MP= Multiple
Pregnancy, SA= Spontaneous Abortion

                Clomiphene         Metformin
                    %                  %

No. of        65 65 (65/100)     35 35 (35/100)
  patient
  given
Ovulation    35 53.84 (35/65)   17 48.57 (17/35)
Conception       23 35.38           15 42.85
                 (23/65)            (15/35)
VP               19 29.23           12 34.28
(>28 wks.)       (19/65)            (12/35)

Complications

OHSS             04 06.15             NIL
                 (04/65)              NIL
MP               03 04.61             NIL
                 (03/65)              NIL
SA           04 06.15 (04/65)   03 08.57 (03/35)

                Clomiphene with          Clomiphene
                   Metformin              with HCG
                       %                      %

No. of       48 (30+18) 48 (48/100)    18 18 (18/100)
  patient
  given
Ovulation       30 62.50 (30/48)      12 66.66 (12/18)
Conception          21 43.75              09 50.00
                    (21/48)                (09/18)
VP                  18 37.50              07 38.88
(>28 wks.)          (18/48)                (07/18)

Complications

OHSS                02 04.16              04 22.22
                    (02/48)                (04/18)
MP                  01 02.08                 NIL
                    (01/48)                  NIL
SA              03 06.25 (03/48)      02 11.11 (02/100)

              Clomiphene with
                 HCG & HMG
                     %

No. of        06 06 (06/100)
  patient
  given
Ovulation    03 50.00 (03/100)
Conception       02 33.33
                  (02/06)
VP               02 33.33
(>28 wks.)        (02/06)

Complications

OHSS             02 33.33
                  (02/06)
MP                  NIL
                    NIL
SA                NIL NIL
COPYRIGHT 2019 Akshantala Enterprises Private Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Research Article
Author:De Pati, Anuradha; Akhtar, Selim; Chattopadhyay, Nibedita; Banerjee, Susanta
Publication:Journal of Evolution of Medical and Dental Sciences
Article Type:Report
Geographic Code:9INDI
Date:Jun 10, 2019
Words:3030
Previous Article:THE ROLE OF DAILY CO-CARBIDOPA THERAPY IN CHRONIC RESTLESS LEG SYNDROME AND ITS ASSOCIATION WITH AUGMENTATION IN A STUDY IN TERTIARY CARE CENTRE IN...
Next Article:A STUDY ON MATERNAL SERUM TOTAL THIOLS AND HIGHLY SENSITIVE C-REACTIVE PROTEIN AS INDICATORS OF OXIDATIVE STRESS AND INFLAMMATION IN PREECLAMPSIA AND...
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |